Precision Medicine in Immuno-Oncology: The Evolving Role of Current and Emerging Biomarkers - Incorporating Biomarkers Into Clinical Practice
Precision Medicine in Immuno-Oncology: The Evolving Role of Current and Emerging Biomarkers -
Incorporating Biomarkers Into Clinical Practice
Release Date: July 31, 2020
Last Reviewed: July 26, 2020
Expiration Date: July 31, 2021
Time to Complete Activity: 0.5 Hours
Michael J. Overman, MD
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Lynette M. Sholl, MD
Associate Professor, Pathology
Harvard Medical School
Associate Pathologist, Pathology
Brigham and Women's Hospital
This activity is provided by Paradigm Medical Communications, LLC.
This activity has been designed to address the educational needs of oncology clinicians and pathologists. It may also be of benefit to pulmonologists, cytotechnologists, researchers, and other healthcare and laboratory professionals interested in immuno-oncology, precision medicine, and/or biomarker research.
Upon proper completion of this activity, participants should be better able to:
- Outline the latest data for the optimal use of immuno-oncology predictive biomarkers, including current and potential future roles, as well as understood limitations
Physician Accreditation Statement
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Educational Review Systems, Inc is an approved provider of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 0.5 hours of continuing nursing education.
Educational Review Systems, Inc is also approved for nursing continuing education by the state of California, the state of Florida, and the District of Columbia.
Pharmacist Accreditation and Designation Statement
Educational Review Systems, Inc is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 0.5 hours (0.05 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
(Universal Activity Number: 0761-9999-20-115-H01-P)
This is a knowledge-based activity.
This activity is jointly provided by Educational Review Systems, Inc and Paradigm Medical Communications, LLC.
PA Continuing Education
PAs may claim a maximum of 0.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Disclosure of Commercial Support
This activity is supported by an educational grant from Bristol-Myers Squibb.
Instructions for Participation
To receive a CE certificate of participation, you should:
- Follow instructions to register or log in with your professional information and complete the pre-activity assessment
- View the online activity in its entirety
- Complete and submit the online posttest and evaluation
A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.
Please note: To claim CPE credit, please make sure you include your date of birth and NABP number. All credit information will be uploaded into CPE Monitor within 30 days.
For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949.
There is no fee required for participation in this activity.
This certified CME activity is designed using HTML5 video. As you navigate the video using the supplied controls, the slides will sync to the speaker.
For Desktops (Windows/Mac)
Microsoft Edge 40 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher, Opera 21 or higher
For Tablets (iPad/Android/Surface)
iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher
Technical Support: If you have any technical problems or playback issues email us at: email@example.com.
Michael J. Overman, MD
Consulting Fees: Array BioPharma Inc; AstraZeneca; Bristol-Myers Squibb Company; CatalYm; Gritstone Oncology; Novartis Pharmaceuticals Corporation; Promega Corporation; Roche; Takeda
Grant/Research Support: AstraZeneca; Bristol-Myers Squibb Company; Merck & Co., Inc; Nouscom
Lynette M. Sholl, MD
Consulting Fees: AstraZeneca; EMD Serono, Inc
Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.
Educational Review Systems, Inc staff members have no financial relationships to disclose.
Independent peer reviewer has no financial relationships to disclose.
Resolution of Conflict of Interest
Paradigm Medical Communications, LLC and Educational Review Systems, Inc have implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CE content in this activity has been independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ANCC Guidelines, ACPE Guidelines, and ACCME’s Standards for Commercial Support of Continuing Medical Education.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.
This CE activity represents the views and opinions of the individual faculty members, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC or Educational Review Systems, Inc Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
If included, signed statements of informed consent granting permission for use have been obtained for all photographs and videos in which an individual can be identified.
As accredited providers, Paradigm Medical Communications, LLC and Educational Review Systems, Inc activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC or Educational Review Systems, Inc
© 2020 Paradigm Medical Communications, LLC, except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.